8-K: Cogent Biosciences Announces Positive Clinical Trial Updates for Bezuclastinib in Systemic Mastocytosis

Cogent Biosciences reported positive updated data from Phase 2 trials of bezuclastinib for advanced and non-advanced systemic mastocytosis at the ASH 2024 conference.

Summary

• Cogent Biosciences announced positive updated data from its Phase 2 APEX trial for advanced systemic mastocytosis (AdvSM) and Phase 2 SUMMIT trial for non-advanced systemic mastocytosis (NonAdvSM).
• The APEX trial, with 32 patients, showed a 52% overall response rate (ORR) across all doses, and an 83% ORR in the 100 mg BID cohort, with a median time to response of 2.2 months.
• The APEX trial also demonstrated significant improvements in biomarkers, with 94% of patients achieving a 50% reduction in serum tryptase levels and 93% of KITD816V-positive patients achieving a 50% reduction in variant allele fraction.
• The SUMMIT trial, focusing on 27 patients in the open-label extension, showed a 56% mean improvement in Total Symptom Score (TSS) and a 49% mean improvement in MC-QoL Total Score at 24 weeks.
• In the SUMMIT trial, 89% of patients had a greater than 50% decrease in serum tryptase levels by four weeks of treatment.
• Enrollment for the SUMMIT Part 2 study is now complete, with 179 patients enrolled, and top-line results are expected in July 2025.
• The company anticipates completing enrollment for APEX Part 2 in Q1 2025 and expects top-line data in mid-2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with strong efficacy and safety data, suggesting a high likelihood of success for bezuclastinib. The completion of enrollment for SUMMIT Part 2 is also a positive sign.

Positives

• Bezuclastinib demonstrated a strong safety and tolerability profile across both trials.
• The majority of adverse events were low grade and reversible.
• Both trials showed significant improvements in patient-reported outcomes and biomarkers.
• The APEX trial showed a high overall response rate, particularly in the 100 mg BID cohort.
• The SUMMIT trial showed rapid and sustained reductions in serum tryptase levels.
• The SUMMIT trial showed a significant improvement in patient symptoms and quality of life.
• The company has completed enrollment for the SUMMIT Part 2 study ahead of schedule.

Negatives

• One patient in the APEX trial was reassessed and reported as a Grade 4 gamma-glutamyl transferase (GGT) elevation case.
• Twelve patients in the APEX trial required dose reductions, eight of whom were treated at a 400 mg daily dose.
• Some patients in the SUMMIT trial experienced hair discoloration and transaminase elevations, though these were mostly reversible.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including those related to clinical trial results and enrollment rates.
• The company may not achieve the forecasts or milestones disclosed in its forward-looking statements.
• There are risks associated with the development and regulatory approval of new drugs.

Future Outlook

The company expects to complete enrollment for APEX Part 2 in Q1 2025 and to have top-line data in mid-2025, and anticipates presenting top-line results from SUMMIT Part 2 in July 2025.

Industry Context

The announcement is significant in the context of the treatment landscape for systemic mastocytosis, a rare disease with limited treatment options, and the positive results could position bezuclastinib as a key therapy.

Comparison to Industry Standards

• Avapritinib and midostaurin are existing treatments for systemic mastocytosis, and the results for bezuclastinib appear to be competitive, particularly in terms of response rates and tolerability.
• The high response rates and biomarker improvements in the APEX trial compare favorably to historical data for other treatments in advanced systemic mastocytosis.
• The patient-reported outcome improvements in the SUMMIT trial are notable, as they address the symptomatic burden of non-advanced systemic mastocytosis, which is a key unmet need.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with systemic mastocytosis may benefit from a new treatment option.
• Employees of Cogent Biosciences may be motivated by the positive progress of the clinical trials.

Next Steps

• The company will complete enrollment for APEX Part 2 in Q1 2025.
• The company will present top-line results from APEX Part 2 in mid-2025.
• The company will present top-line results from SUMMIT Part 2 in July 2025.

Key Dates

Keywords

bezuclastinib, systemic mastocytosis, clinical trial, APEX, SUMMIT, hematology, ASH 2024, drug development, biomarkers, patient reported outcomes